China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an investigator-initiated trial (ITT) for its KJ-C2320, a universal chimeric antigen receptor (CAR)-T cell therapy targeting recurrent/refractory acute myeloid leukemia (R/R AML). This milestone marks a significant step forward in the development of innovative treatments for this challenging hematologic malignancy.
KJ-C2320: Universal CAR-T Therapy
KJ-C2320 is a CD38-targeted CAR-T therapy developed on CARsgen’s proprietary THANK-uCAR platform. The platform enables the generation of universal CAR-T cells with enhanced expansion and persistence by modifying donor-derived T cells. This approach aims to overcome the limitations of traditional CAR-T therapies by providing a more scalable and accessible treatment option for patients with R/R AML.
Clinical Trial and Future Implications
The initiation of the ITT for KJ-C2320 demonstrates CARsgen’s commitment to advancing universal CAR-T therapies. The trial will evaluate the safety and efficacy of KJ-C2320 in patients with R/R AML, potentially offering a new therapeutic avenue for those who have exhausted other treatment options. This development underscores CARsgen’s ongoing efforts to innovate in the field of cell therapy and address significant unmet medical needs in oncology.-Fineline Info & Tech
Leave a Reply